- Home
- BIIB vs PKG Comparison
BIIB vs PKG Comparison
Compare BIIB & PKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PKG
- Stock Information
- Founded
- BIIB 1978
- PKG 1867
- Country
- BIIB United States
- PKG United States
- Employees
- BIIB N/A
- PKG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PKG Containers/Packaging
- Sector
- BIIB Health Care
- PKG Consumer Discretionary
- Exchange
- BIIB Nasdaq
- PKG Nasdaq
- Market Cap
- BIIB 18.7B
- PKG 18.4B
- IPO Year
- BIIB 1991
- PKG 2000
- Fundamental
- Price
- BIIB $127.70
- PKG $194.91
- Analyst Decision
- BIIB Buy
- PKG Buy
- Analyst Count
- BIIB 27
- PKG 6
- Target Price
- BIIB $187.96
- PKG $221.17
- AVG Volume (30 Days)
- BIIB 1.5M
- PKG 656.2K
- Earning Date
- BIIB 07-31-2025
- PKG 07-23-2025
- Dividend Yield
- BIIB N/A
- PKG 2.57%
- EPS Growth
- BIIB 31.67
- PKG 25.72
- EPS
- BIIB 10.45
- PKG 10.02
- Revenue
- BIIB $9,997,000,000.00
- PKG $8,640,800,000.00
- Revenue This Year
- BIIB N/A
- PKG $7.02
- Revenue Next Year
- BIIB N/A
- PKG $5.63
- P/E Ratio
- BIIB $12.22
- PKG $19.45
- Revenue Growth
- BIIB 3.36
- PKG 8.98
- 52 Week Low
- BIIB $110.04
- PKG $172.72
- 52 Week High
- BIIB $207.59
- PKG $250.82
- Technical
- Relative Strength Index (RSI)
- BIIB 46.35
- PKG 44.64
- Support Level
- BIIB $124.56
- PKG $191.13
- Resistance Level
- BIIB $134.16
- PKG $194.40
- Average True Range (ATR)
- BIIB 3.98
- PKG 3.85
- MACD
- BIIB -0.02
- PKG -1.47
- Stochastic Oscillator
- BIIB 46.23
- PKG 25.13
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.